Cargando…

In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India

Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is conside...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathew, Shilu, Faheem, Muhammad, Archunan, Govindaraju, Ilyas, Muhammad, Begum, Nargis, Jahangir, Syed, Qadri, Ishtiaq, Qahtani, Mohammad Al, Mathew, Shiny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076477/
https://www.ncbi.nlm.nih.gov/pubmed/25002815
http://dx.doi.org/10.4137/BBI.S15211
_version_ 1782323488934068224
author Mathew, Shilu
Faheem, Muhammad
Archunan, Govindaraju
Ilyas, Muhammad
Begum, Nargis
Jahangir, Syed
Qadri, Ishtiaq
Qahtani, Mohammad Al
Mathew, Shiny
author_facet Mathew, Shilu
Faheem, Muhammad
Archunan, Govindaraju
Ilyas, Muhammad
Begum, Nargis
Jahangir, Syed
Qadri, Ishtiaq
Qahtani, Mohammad Al
Mathew, Shiny
author_sort Mathew, Shilu
collection PubMed
description Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is considered to be the superlative target of antiviral compounds. Novel drug inhibitors of HCV are in need to complement or replace the current treatments such as pegylated interferon’s and ribavirin as they are partially booming and beset with various side effects. Our study was conducted to predict 3D structure of capsid core protein of HCV from northern part of India. Core, the capsid protein of HCV, handles the assembly and packaging of HCV RNA genome and is the least variable of all the ten HCV proteins among the six HCV genotypes. Therefore, we screened four phytochemicals inhibitors that are known to disrupt the interactions of core and other HCV proteins such as (a) epigallocatechin gallate (EGCG), (b) ladanein, (c) naringenin, and (d) silybin extracted from medicinal plants; targeted against active site of residues of HCV-genotype 3 (G3) (Q68867) and its subtypes 3b (Q68861) and 3g (Q68865) from north India. To study the inhibitory activity of the recruited flavonoids, we conducted a quantitative structure–activity relationship (QSAR). Furthermore, docking interaction suggests that EGCG showed a maximum number of hydrogen bond (H-bond) interactions with all the three modeled capsid proteins with high interaction energy followed by naringenin and silybin. Thus, our results strongly correlate the inhibitory activity of the selected bioflavonoid. Finally, the dynamic predicted capsid protein molecule of HCV virion provides a general avenue to target structure-based antiviral compounds that support the hypothesis that the screened inhibitors for viral capsid might constitute new class of potent agents but further confirmation is necessary using in vitro and in vivo studies.
format Online
Article
Text
id pubmed-4076477
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-40764772014-07-07 In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India Mathew, Shilu Faheem, Muhammad Archunan, Govindaraju Ilyas, Muhammad Begum, Nargis Jahangir, Syed Qadri, Ishtiaq Qahtani, Mohammad Al Mathew, Shiny Bioinform Biol Insights Original Research Hepatitis viral infection is a leading cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). Over one million people are estimated to be persistently infected with hepatitis C virus (HCV) worldwide. As capsid core protein is the key element in spreading HCV; hence, it is considered to be the superlative target of antiviral compounds. Novel drug inhibitors of HCV are in need to complement or replace the current treatments such as pegylated interferon’s and ribavirin as they are partially booming and beset with various side effects. Our study was conducted to predict 3D structure of capsid core protein of HCV from northern part of India. Core, the capsid protein of HCV, handles the assembly and packaging of HCV RNA genome and is the least variable of all the ten HCV proteins among the six HCV genotypes. Therefore, we screened four phytochemicals inhibitors that are known to disrupt the interactions of core and other HCV proteins such as (a) epigallocatechin gallate (EGCG), (b) ladanein, (c) naringenin, and (d) silybin extracted from medicinal plants; targeted against active site of residues of HCV-genotype 3 (G3) (Q68867) and its subtypes 3b (Q68861) and 3g (Q68865) from north India. To study the inhibitory activity of the recruited flavonoids, we conducted a quantitative structure–activity relationship (QSAR). Furthermore, docking interaction suggests that EGCG showed a maximum number of hydrogen bond (H-bond) interactions with all the three modeled capsid proteins with high interaction energy followed by naringenin and silybin. Thus, our results strongly correlate the inhibitory activity of the selected bioflavonoid. Finally, the dynamic predicted capsid protein molecule of HCV virion provides a general avenue to target structure-based antiviral compounds that support the hypothesis that the screened inhibitors for viral capsid might constitute new class of potent agents but further confirmation is necessary using in vitro and in vivo studies. Libertas Academica 2014-06-23 /pmc/articles/PMC4076477/ /pubmed/25002815 http://dx.doi.org/10.4137/BBI.S15211 Text en © 2014 the author(s), publisher and licensee Libertas Academica Ltd. This is an open-access article distributed under the terms of the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Original Research
Mathew, Shilu
Faheem, Muhammad
Archunan, Govindaraju
Ilyas, Muhammad
Begum, Nargis
Jahangir, Syed
Qadri, Ishtiaq
Qahtani, Mohammad Al
Mathew, Shiny
In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
title In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
title_full In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
title_fullStr In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
title_full_unstemmed In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
title_short In Silico Studies of Medicinal Compounds Against Hepatitis C Capsid Protein from North India
title_sort in silico studies of medicinal compounds against hepatitis c capsid protein from north india
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4076477/
https://www.ncbi.nlm.nih.gov/pubmed/25002815
http://dx.doi.org/10.4137/BBI.S15211
work_keys_str_mv AT mathewshilu insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT faheemmuhammad insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT archunangovindaraju insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT ilyasmuhammad insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT begumnargis insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT jahangirsyed insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT qadriishtiaq insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT qahtanimohammadal insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia
AT mathewshiny insilicostudiesofmedicinalcompoundsagainsthepatitisccapsidproteinfromnorthindia